MAPK8 and Parkinson disease: From previous studies, SP administrated intracerebroventricularly in a suitable concentration can inhibit both of the activation of JNK pathway and the expression of caspase-3 [1, 16], showing significant functional improvement of Parkinson’s disease [9–11].